MedTrace Logo

Growth Hormone and Dehydroepiandrosterone Role in Vitro Fertilization

NCT07323329 · Status: RECRUITING · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 165

Last updated 2026-01-07

No results posted yet for this study

Summary

The goal of this study is to evaluate the role of Somatropin and Dehydroepiandrosterone (DHEA) on ovarian reserve parameters and intracytoplasmic sperm injection (ICSI) outcome in poor ovarian responder.

The main question it aims to answer is:

Which intervention is more effective in increasing number and size of follicles? Participants will be followed 1 month before starting induction in growth hormone and 12 weeks for DHEA and through intracytoplasmic sperm injection (ICSI) cycle.

Conditions

Interventions

DRUG

Somatropin (4IU for 1 month) plus, folic acid 400 mcg per day.

Patients will receive Somatropin (4IU for 1 month)1 S.C injection every 3 days for at least 1 month plus, folic acid 400 mcg per day.

DRUG

DHEA plus folic acid 400mcg per day

Patients will receive DHEA 50 mg twice per day for 12 weeks plus folic acid 400mcg per day

DIETARY_SUPPLEMENT

control group

Patients will receive folic acid 400 mcg per day

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-10
Primary Completion
2026-10-15
Completion
2026-11-12

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07323329 on ClinicalTrials.gov